These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31157717)

  • 1. National Patterns of Filled Prescriptions and Third-Line Treatment Utilization for Privately Insured Women With Overactive Bladder.
    Linder BJ; Gebhart JB; Elliott DS; Van Houten HK; Sangaralingham LR; Habermann EB
    Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):e261-e266. PubMed ID: 31157717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States.
    Jiang J; Patil D; Traore EJ; Hammett J; Filson CP
    Urology; 2020 Aug; 142():87-93. PubMed ID: 32437771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
    Murray B; Hessami SH; Gultyaev D; Lister J; Dmochowski R; Gillard KK; Stanisic S; Tung A; Boer R; Kaplan S
    J Comp Eff Res; 2019 Jan; 8(1):61-71. PubMed ID: 30511584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments.
    Kirby AC; Park S; Cook SB; Odem-Davis K; Gore JL; Wolff EM
    Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):431-436. PubMed ID: 32265405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
    Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
    Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
    Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
    Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients.
    Syan R; Zhang CA; Enemchukwu EA
    Urology; 2020 Aug; 142():81-86. PubMed ID: 32439551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder.
    Shepherd JP; Carter-Brooks CM; Chermanksy C
    Int Urogynecol J; 2018 Aug; 29(8):1213-1219. PubMed ID: 29671033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
    Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
    Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry.
    Jericevic D; Shapiro K; Bowman M; Vélez CA; Mbassa R; Fang R; Van Kuiken M; Brucker BM
    Urol Pract; 2024 Mar; 11(2):394-401. PubMed ID: 38226920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
    Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
    J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
    Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
    JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
    Ju R; Garrett J; Wu JM
    Int Urogynecol J; 2014 Apr; 25(4):479-84. PubMed ID: 24158462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
    Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
    Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina.
    Doggweiler R
    J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846
    [No Abstract]   [Full Text] [Related]  

  • 19. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.
    Alhasso AA; McKinlay J; Patrick K; Stewart L
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003193. PubMed ID: 17054163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Nonadherence to Overactive Bladder Medications in an Integrated Managed Care Health Care System.
    Rashid N; Vassilakis M; Lin KJ; Kristy R; Ng DB
    J Manag Care Spec Pharm; 2017 Apr; 23(4):484-493. PubMed ID: 28345439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.